UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 31, 2020
ORTHOFIX MEDICAL INC.
(Exact name of Registrant as specified in its charter)
Delaware | | 0-19961 | | 98-1340767 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | | |
3451 Plano Parkway Lewisville, Texas | | 75056 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (214) 937-2000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common stock, $0.10 par value per share | | OFIX | | Nasdaq Global Select Market |
Item 5.02. | Departure of Directors or Principal Officers. |
On March 31, 2020, Orthofix Medical Inc. (the “Company”) and Michael M. Finegan determined that Mr. Finegan would depart as an employee and executive officer of the Company as of July 4, 2020. Pursuant to the Change in Control and Severance Agreement entered into by the Company and Mr. Finegan on November 1, 2016, Mr. Finegan will be entitled to receive the “Severance Amount” and “Accrued Amounts” described in Section 3 thereof. The Company has expressed its gratitude to Mr. Finegan for his many years of dedicated and loyal service to the Company.
Item 9.01. | Financial Statements and Exhibits. |
(d) | Exhibits |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
Orthofix Medical Inc. | |
By: | | /s/ Kimberley A. Elting | |
| | Kimberley A. Elting Chief Legal and Administrative Officer | |
Date: April 1, 2020
